Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm
Mandate

Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm

December 16, 2022 Capital Markets and Public M&A Corporate Tax

Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.

Acrinova is a real estate group with a focus on southern Sweden and on commercial properties. The Company offers comprehensive services as owner, manager and developer of real estate. Acrinova has its headquarter in Malmö, Sweden. The Company is uplisting from Nasdaq First North Premier Growth Market, where the Company's shares have been listed since 2019.

Vinge’s team has primarily consisted of Linnéa Sellström, Emma Brolund, Lorin Arabi and Michaela Ådén (Capital Markets and Public M&A), as well as Victor Ericsson, Emelie Svanberg and Maja Prahl (Corporate Tax).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025